Mitsubishi Tanabe Lines Up Trials For Hepatitis C Therapy
This article was originally published in PharmAsia News
TOKYO - As Massachusetts-based Vertex Pharmaceuticals this month launches a closely watched Phase III trial of investigational hepatitis C therapy telaprevir, Osaka-based Mitsubishi Tanabe Pharma has been enrolling Japanese patients for three Phase I/II trials of the drug, an oral protease inhibitor
You may also be interested in...
WuXi Pharma has systems in place to soften the impact of cost inflation issues expected to impact the Chinese pharma industry, according to Oppenheimer analyst Charles Rhyee
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).